|
|
|
| New progress in the treatment of gastroparesis |
| Department of Gastrointestinal Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China |
|
|
|
|
Abstract Gastroparesis (Gp) is a chronic disease that presents with clinical symptoms of nausea, vomiting, early satiety, bloating and abdominal pain, which is caused by delayed gastric emptying. These chronic symptoms have adverse impacts on the physiology, psychology and life quality of patients. Studies found that the mortality of patients with gastroparesis was higher than those without gastroparesis, which showed that gastroparesis has become a serious threa to human health. In last decade, there were some updates on the pathogenesis and management of gastroparesis. Studies found that gastroparesis were associated with decreased interstitial cells of Cajal (ICC), which caused the insufficience and allorhythmia of smooth muscle cells in the antrum. Therefore, endoscopic implantable gastric electric stimulator or pyloroplasty should be the choice for refractory gastroparesis. In addition, researchers found that some patients with gastroparesis who did not respond to drugs or surgery benefitted from immunotherapy. Not surprisingly, patients suffering from chronic gastrointestinal conditions frequently report psychological symptoms, such as anxiety and depression. So psychological evaluation and management should be considered for patients with gastroparesis. Moreover, identifying the risk factors of gastroparesis might help prevent occurrence of gastroparesis. At last, exploring novel treatment methods, such as stem cell transplantation, may bring new hope for gastroparesis.
|
|
|
|
|
|
|
|
|
2018, Vol. 5 
